Mise au point de l'EFSA sur le bisphenol A

The European Food Safety Authority’s AFC Panel[1] has issued a further scientific opinion on a specific aspect of the chemical bisphenol A (BPA), concerning its elimination from the body and how that relates to the risk assessment of BPA for humans. The aim was to take into account recent data and consider any implications for the existing EFSA advice on BPA set out in its 2006 opinion, which concluded that exposure to BPA is well below the Tolerable Daily Intake (TDI). People are exposed to BPA which may be present in food through its use in certain food contact materials such as baby bottles and cans. The conclusions of the Panel are that after exposure to BPA the human body rapidly metabolises and eliminates the substance. This represents an important metabolic difference compared with rats. EFSA will continue to monitor closely scientific findings regarding BPA and any related health effects. The AFC Panel, in its final session, took into account both the previous and the most recent information and data available on the way that BPA and related substances are handled in the human body. The Panel concluded that the exposure of the human foetus to BPA would be negligible because the mother rapidly metabolises and eliminates BPA from her body. The scientists also concluded that newborns are similarly able to metabolise and eliminate BPA at doses below 1 milligram per kilogram of body weight per day. This implies that newborns could effectively clear BPA at levels far in excess of the TDI of 0.05 mg/kg bw set by the Panel and therefore its 2006 risk assessment remains valid. The Panel considered the significant differences between humans and rodents, such as the fact that people metabolise and excrete BPA far more quickly than rodents. This body of evidence further limits the relevance of low-dose effects of BPA reported in some rodent studies used for human risk assessment. In its previous risk assessment, the Panel derived a TDI of 0.05 mg/kg body weight based on the no-observed-adverse-effect level (NOAEL) of 5 milligram/kg body weight/day for effects in rats and included an uncertainty factor of 100. In this latest assessment,

Voir : http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1211902017373.htm



Vos réactions

Soyez le premier à réagir !

Les réactions aux articles sont réservées aux professionnels de santé inscrits
Elles ne seront publiées sur le site qu’après modération par la rédaction (avec un délai de quelques heures à 48 heures). Sauf exception, les réactions sont publiées avec la signature de leur auteur.

Réagir à cet article